Top

Published in:

Open Access 01-12-2017 | Research article

Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease

Authors: Sandro Félix Perazzio, Paulo Vitor Soeiro-Pereira, Viviane Cardoso dos Santos, Marlon Vilela de Brito, Bruno Salu, Maria Luiza Vilela Oliva, Anne Margherite Stevens, Alexandre Wagner Silva de Souza, Hans D. Ochs, Troy R. Torgerson, Antonio Condino-Neto, Luis Eduardo Coelho Andrade

Published in: Arthritis Research & Therapy | Issue 1/2017

Abstract

Background

Studies have suggested that soluble factors in plasma from patients with active (aBD) and inactive (iBD) Behçet’s disease (BD) stimulate neutrophil function. Soluble CD40 ligand (sCD40L) is an important mediator of inflammation in BD. Its expression and effect on neutrophil oxidative burst and neutrophil extracellular trap (NET) release have not been characterized. In this study, we sought to investigate the role of plasma and the CD40L pathway on NET release and the oxidative burst profile in patients with aBD and iBD.

Methods

Neutrophils and peripheral blood mononuclear cells (PBMCs) were obtained from patients with aBD (n = 30), patients with iBD (n = 31), and healthy control subjects (HCs; n = 30). sCD40L plasma concentration was determined in individual samples. A pool of plasma for each group was created. In some experiments, plasma pools were treated with recombinant CD40 (rhCD40-muIg) for sCD40L blockade. NET release and H₂O₂/O₂ ⁻ production were determined after stimulation with phorbol 12-myristate 13-acetate, sCD40L, or plasma pool. Flow cytometric analysis was performed to evaluate the expression of (1) CD40, Mac-1, and phosphorylated NF-κB p65 on neutrophils and monocytes and (2) CD40L on activated T cells and platelets. CD40L gene expression in PBMCs was determined by qRT-PCR.

Results

sCD40L plasma levels were significantly higher in patients with iBD (median 17,234, range 2346–19,279 pg/ml) and patients with aBD (median 18,289, range 413–19,883 pg/ml) than in HCs (median 47.5, range 33.7–26.7 pg/ml; p < 0.001). NET release was constitutively increased in BD compared with HC. NET release and H₂O₂/O₂ ⁻ were higher after stimulation with sCD40L or BD plasma and decreased after sCD40L blockade. Mac-1 expression was constitutively increased in neutrophils of patients with aBD (88.7 ± 13.2% of cells) and patients with iBD (89.2 ± 20.1% of cells) compared with HC (27.1 ± 18.8% of cells; p < 0.01). CD40 expression on phagocytes and CD40L expression on platelets were similar in the three groups. PBMCs as well as nonactivated and activated CD4⁺ T cells from patients with BD showed higher CD40L expression.

Conclusions

Plasma from patients with aBD exerts a stimulus on NET release and oxidative burst, probably induced by sCD40L.

Available only for authorised users

Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S6–12.PubMed

Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, Yoshikawa H, Kaneko F, Suzuki T, Suzuki N. Excessive CD4⁺ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet’s disease. Clin Exp Immunol. 2012;168(1):68–74.CrossRefPubMedPubMedCentral

Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T. Excessive function of peripheral blood neutrophils from patients with Behcet’s disease and from HLA-B51 transgenic mice. Arthritis Rheum. 1995;38(3):426–33.CrossRefPubMed

Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet’s disease. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S19–24.PubMed

Atalay G, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. The effects of nitric oxide donors and inhibitors on neutrophil functions in Behcet’s disease. Clin Exp Rheumatol. 2002;20(4 Suppl 26):S17–20.PubMed

Tekeli A, Tekeli O, Ozdemir O. In vitro candidacidal effect of polymorphonuclear neutrophils of Behçet’s patients with or without ocular involvement. APMIS. 2001;109(2):108–12.CrossRefPubMed

Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behçet’s disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003;87(9):1175–83.CrossRefPubMedPubMedCentral

Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, Bambara LM. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet’s disease. J Rheumatol. 1997;24(7):1332–6.PubMed

Perazzio SF, Soeiro-Pereira PV, de Souza AW, Condino-Neto A, Andrade LE. Behçet’s disease heterogeneity: cytokine production and oxidative burst of phagocytes are altered in patients with severe manifestations. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S85–95.PubMed

10.

Neves FS, Carrasco S, Goldenstein-Schainberg C, Goncalves CR, de Mello SB. Neutrophil hyperchemotaxis in Behcet’s disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol. 2009;28(12):1403–10.CrossRefPubMed

11.

Yoshida T, Tanaka M, Sotomatsu A, Okamoto K, Hirai S. Serum of Behcet’s disease enhances superoxide production of normal neutrophils. Free Radic Res. 1998;28(1):39–44.CrossRefPubMed

12.

Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, Bonnefoy JY, Gauchat JF. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem. 1996;271(11):5965–7.CrossRefPubMed

13.

Hassan GS, Merhi Y, Mourad W. CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology. 2012;217(5):521–32.CrossRefPubMed

14.

Fernández Bello I, Álvarez MT, López-Longo FJ, Arias-Salgado EG, Martín M, Jiménez-Yuste V, de la Rúa Rodríguez A, Butta NV. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. Thromb Haemost. 2012;107(1):88–98.CrossRefPubMed

15.

Jin R, Yu S, Song Z, Zhu X, Wang C, Yan J, Wu F, Nanda A, Granger DN, Li G. Soluble CD40 ligand stimulates CD40-dependent activation of the β2 integrin Mac-1 and protein kinase C zeda (PKCζ) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst. PLoS One. 2013;8(6):e64631.CrossRefPubMedPubMedCentral

16.

Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784–90.CrossRefPubMedPubMedCentral

17.

International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078–80.

18.

de Souza NF, Muniz Caldas CA, de Martins Medeiros D, de Bertacini Moraes JC, Gonçalves CR. Cross-cultural adaptation of simplified version(s) of Behçet’s Disease Current Activity Form (BDCAF) and comparison between two different instruments with Brazilian versions for evaluating Behçet’s Disease Activity: BR-BDCAF and BR-BDCAF(s) [in Portuguese]. Rev Bras Reumatol. 2009;49(1):20–31.

19.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644–55.CrossRefPubMed

20.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.CrossRefPubMed

21.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630–40.CrossRefPubMed

22.

Soeiro-Pereira PV, Falcai A, Kubo CA, Oliveira-Júnior EB, Marques OC, Antunes E, Condino-Neto A. BAY 41-2272, a soluble guanylate cyclase agonist, activates human mononuclear phagocytes. Br J Pharmacol. 2012;166(5):1617–30.CrossRefPubMedPubMedCentral

23.

Hatanaka E, Levada-Pires AC, Pithon-Curi TC, Curi R. Systematic study on ROS production induced by oleic, linoleic, and gamma-linolenic acids in human and rat neutrophils. Free Radic Biol Med. 2006;41(7):1124–32.CrossRefPubMed

24.

Maguire O, O’Loughlin K, Minderman H. Simultaneous assessment of NF-κB/p65 phosphorylation and nuclear localization using imaging flow cytometry. J Immunol Methods. 2015;423:3–11.CrossRefPubMedPubMedCentral

25.

Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231–41.CrossRefPubMedPubMedCentral

26.

Cabral-Marques O, Schimke LF, Pereira PV, Falcai A, de Oliveira JB, Hackett MJ, Errante PR, Weber CW, Ferreira JF, Kuntze G, et al. Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol. 2012;32(2):212–20.CrossRefPubMed

27.

Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996;97(9):2063–73.CrossRefPubMedPubMedCentral

28.

Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol. 2002;103(1):54–62.CrossRefPubMed

29.

Lee R. Revisiting the role of sCD40L as an inflammatory biomarker in a clinical model of acute myocardial infarction. Circ Res. 2015;116(4):e26.CrossRefPubMed

30.

Wang JH, Zhang YW, Zhang P, Deng BQ, Ding S, Wang ZK, Wu T, Wang J. CD40 ligand as a potential biomarker for atherosclerotic instability. Neurol Res. 2013;35(7):693–700.CrossRefPubMedPubMedCentral

31.

Santilli F, Liani R, Di Fulvio P, Formoso G, Simeone P, Tripaldi R, Ueland T, Aukrust P, Davì G. Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thromb Haemost. 2016;116(6):1089–99.CrossRefPubMed

32.

Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanç M, Capo C. Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20(9):1544–9.PubMed

33.

Sellam J, Proulle V, Jüngel A, Ittah M, Miceli Richard C, Gottenberg JE, Toti F, Benessiano J, Gay S, Freyssinet JM, et al. Increased levels of circulating microparticles in primary Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther. 2009;11(5):R156.CrossRefPubMedPubMedCentral

34.

Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets. 2008;19(2):146–54.CrossRefPubMed

35.

Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol. 2004;31(3):514–9.PubMed

36.

Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K. Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clin Rheumatol. 2003;22(1):37–9.CrossRefPubMed

37.

Ciferská H, Horák P, Hermanová Z, Ordeltová M, Zadrazil J, Tichý T, Scudla V. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol. 2007;26(5):723–8.CrossRefPubMed

38.

Rahman M, Zhang S, Chew M, Ersson A, Jeppsson B, Thorlacius H. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg. 2009;250(5):783–90.CrossRefPubMed

39.

Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107(21):9813–8.CrossRefPubMedPubMedCentral

40.

Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014;16(3):R122.CrossRefPubMedPubMedCentral

41.

Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, Ishizu A. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25(5):990–7.CrossRefPubMedPubMedCentral

42.

Yipp BG, Kubes P. NETosis: how vital is it? Blood. 2013;122(16):2784–94.CrossRefPubMed

43.

Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, Yang X, Zhou X, Zhang Y, Gillooly K, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192(9):4083–92.CrossRefPubMed

44.

Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, Mitchell N, Esfandiari E, Wagner F, Oliver R. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015;24(10):1045–56.CrossRefPubMed

45.

Wood SC, Lu G, Burrell BE, Bishop DK. Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells. Am J Transplant. 2008;8(10):2037–48.CrossRefPubMedPubMedCentral

46.

Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141(4):545–8.CrossRefPubMed

47.

Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis CC. Serum of patients with Behcet’s disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology. 2003;206(3):225–32.CrossRefPubMed

48.

Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S, Kaklamanis P, Orfanos CE. Adamantiades-Behcet’s disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res. 2000;292(6):279–84.CrossRefPubMed

49.

Ertenli I, Kiraz S, Calguneri M, Celik I, Erman M, Haznedaroglu IC, Kirazli S. Synovial fluid cytokine levels in Behcet’s disease. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S37–41.PubMed

50.

Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41.CrossRefPubMed

51.

Jackman RW, Rhoads MG, Cornwell E, Kandarian SC. Microtubule-mediated NF-κB activation in the TNF-α signaling pathway. Exp Cell Res. 2009;315(19):3242–9.CrossRefPubMedPubMedCentral

52.

Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol. 2008;153(6):1288–95.CrossRefPubMedPubMedCentral

Title: Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease
Authors: Sandro Félix Perazzio
Paulo Vitor Soeiro-Pereira
Viviane Cardoso dos Santos
Marlon Vilela de Brito
Bruno Salu
Maria Luiza Vilela Oliva
Anne Margherite Stevens
Alexandre Wagner Silva de Souza
Hans D. Ochs
Troy R. Torgerson
Antonio Condino-Neto
Luis Eduardo Coelho Andrade
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/s13075-017-1443-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts

Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis

Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis

New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis

The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page